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Abstract
Background—Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations are 
common in acute myeloid leukemia (AML) and are associated with rapid relapse and short 
survival. In relapsed/refractory (R/R) AML, the clinical benefit of FLT3 inhibitors has been 
limited by rapid generation of resistance mutations, especially FLT3-D835. Gilteritinib is a potent, 
highly selective oral FLT3/AXL inhibitor with preclinical activity against FLT3-ITD and FLT3-
D835 mutations. The aim of this Phase 1/2 study was to assess the safety, tolerability, and 
pharmacokinetic (PK) effects of gilteritinib in FLT3 mutation-positive (FLT3mut+) R/R AML.
Methods—This ongoing pharmacodynamic-driven Phase 1/2 trial (NCT02014558) enrolled 
subjects from October 2013 to August 2015 who were aged ≥18 years and were either refractory 
to induction therapy or had relapsed after achieving remission with prior therapy. Subjects were 
enrolled in one of seven dose-escalation or dose-expansion cohorts that were assigned to receive 
once-daily doses of oral gilteritinib (20, 40, 80, 120, 200, 300, or 450 mg). Cohort expansion was 
based on safety/tolerability, FLT3 inhibition in correlative assays, and antileukemic activity; the 
120 and 200 mg dose cohorts were further expanded to include FLT3mut+ patients only. Safety and 
tolerability, and PK effects were the primary endpoints; antileukemic response was the main 
secondary endpoint. Safety and tolerability were assessed by monitoring dose-limiting toxicities 
and treatment-emergent adverse events, and safety assessments (eg, clinical laboratory evaluations, 
electrocardiograms) in the Safety Analysis Set.
Findings—A total of 252 adults with R/R AML, including 58 with wild-type FLT3 and 194 with 
FLT3 mutations (FLT3-ITD, n=162; FLT3-D835, n=16; FLT3-ITD and -D835, n=13; other, n=3), 
received oral gilteritinib (20–450 mg) once daily in one of seven dose-escalation (n=23) or dose-
expansion (n=229) cohorts. Gilteritinib was well tolerated in this heavily pretreated population; 
Grade 3 diarrhea and hepatic transaminase elevation limited dosing above 300 mg/d. The most 
common Grade 3/4 adverse events were febrile neutropenia (39%; n=97/252), anemia (24%; 
n=61/252), thromobocytopenia (13%; n=33/252), sepsis (11%; n=28/252), and pneumonia (11%; 
n=27/252). Serious adverse events in ≥5% of patients were febrile neutropenia (31%; n=78/252), 
progressive disease (17%; n=43/252), sepsis (14%; n=36/252), pneumonia (11%; n=27/252), and 
acute renal failure (10%; n=25/252), pyrexia (8%; n=21/252), bacteremia (6%; n=14/252), and 
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respiratory failure (6%; n=14/252). Gilteritinib demonstrated consistent, potent inhibition of FLT3 
phosphorylation at doses ≥80 mg/d in correlative assays. While responses were observed across all 
dose levels regardless of FLT3 mutation status (overall response rate [ORR]=40%), response rate 
was improved in FLT3mut+ patients at doses ≥80 mg/d (ORR=52%). Among patients with FLT3-
ITD, the additional presence of FLT3-D835 did not alter response rate; patients with only FLT3-
D835 responded less frequently.
Interpretation—Gilteritinib had a favorable safety profile and generated potent FLT3 inhibition 
leading to high rates of antileukemic responses in patients with FLT3mut+ R/R AML. These 
findings confirm that FLT3 is a high-value target in R/R AML and that long-term success of 
therapeutic FLT3 inhibition in AML is optimized by agents with potent, selective, and sustained 
activity against FLT3-ITD mutations and FLT3 tyrosine kinase domain mutations.
Funding—This study was funded by Astellas Pharma, Inc., by a National Cancer Institute 
Leukemia Specialized Program of Research Excellence grant (CA100632) awarded to Drs Mark 
Levis and Jorge Cortes, and by Associazione Italiana Ricerca sul Cancro awarded to Professor 
Giovanni Martinelli.
Keywords
FLT3 inhibition; acute myeloid leukemia; relapsed/refractory; tyrosine kinase inhibitor
INTRODUCTION
Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute 
myeloid leukemia (AML), with mutations occurring in up to 30% of patients.1–3 Two 
distinct activating FLT3 mutations occur at different hotspots: internal tandem duplications 
in the juxtamembrane domain (FLT3-ITD)4 and point mutations in the tyrosine kinase 
domain (FLT3-TKD), most commonly at codon D835.5 Clinically, FLT3 mutations are 
associated with an aggressive disease course; FLT3-ITD mutations are strong predictors of 
rapid relapse and short overall survival (OS) after chemotherapy.2
Development of drugs that effectively target mutated FLT3 has been challenging. Initial 
FLT3 inhibitors had poor bioavailability, limited potency, inadequate kinase specificity, low 
response rates, and short response duration.6–9 Although some FLT3 inhibitors, including 
the multi-kinase inhibitor sorafenib, generated significant antileukemic effects,10,11 response 
rates were variable and typically transient in the FLT3-ITD AML population.10,12–14 
Furthermore, treatment resistance generally emerged within a few weeks of treatment 
initiation.15–17 One mechanism of treatment resistance is the development of secondary 
FLT3-TKD mutations.15–17 As such, gilteritinib (ASP2215), an oral FLT3/AXL inhibitor, 
was designed to specifically target patients with FLT3-ITD mutations and address the 
limitations of other FLT3-targeted therapies.
In vitro, gilteritinib has shown selective kinase inhibition of FLT3 and highly potent activity 
against FLT3 receptors with ITD and TKD mutations.18 Gilteritinib has demonstrated 
antileukemic activity in cell lines expressing FLT3-D835 mutations, suggesting it may be 
effective against the most commonly acquired point mutation conferring resistance to other 
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FLT3 inhibitors.18 Moreover, gilteritinib inhibits AXL,18 an oncogenic tyrosine kinase 
frequently overexpressed in AML19 that facilitates FLT3 activation and has been implicated 
in FLT3 inhibitor resistance.20,21 An investigation of the inhibitory effects of gilteritinib 
against 78 different kinases demonstrated that gilteritinib was a strong inhibitor of FLT3 and 
AXL as well as anaplastic lymphoma kinase (ALK), and leukocyte receptor tyrosine kinase 
(LTK).22 In cell-based assays the IC50 was 1–2 nM for FLT3 and 102 nM for c-Kit.18 In 
vitro assays also demonstrated that gilteritinib had weaker activity against FLT3-F691 
gatekeeper mutations requiring higher concentrations to achieve IC50 than those observed 
for FLT3-ITD and FLT3-D835.18 Based on these preclinical findings, a pharmacodynamic-
driven, first-in-human phase 1/2 trial was conducted in adult patients with relapsed/
refractory (R/R) AML (NCT02014558). The primary objectives were to assess the safety 
and tolerability of gilteritinib and to determine the maximum tolerated dose (MTD). 
Additionally, we sought to define the optimal phase 3 dose, based on clinical response and in 
vivo FLT3 inhibition, and establish the pharmacokinetic (PK) profile of gilteritinib. A key 
secondary objective was to assess the antileukemic activity in FLT3-mutation positive 
(FLT3mut+) and wild-type FLT3 (FLT3WT) AML patient populations.
METHODS
Study Design and Participants
This international, open-label, Phase 1/2, dose-escalation/dose-expansion study was 
conducted from October 2013 through November 2015 across 28 sites in the United States, 
France, Germany, and Italy. The database was locked for final analysis in November 2015 
and data cleaning was completed by May 2016. The study had seven dose-escalation cohorts 
(20–450 mg) with ≥3 patients enrolled at each dose level (Figure 1). The decision to proceed 
to the next dose cohort was made by the dose-escalation committee (Supplemental 
Appendix, page 1) and followed an accelerated titration design. Dose escalation continued 
until ≥2 dose-limiting toxicities (DLTs) were observed in a cohort of three to six patients; 
when ≥2 DLTs occurred in a dose level, the next lower dose level was declared the MTD. 
Safety in all dose cohorts was monitored with respect to DLTs using the Bayesian continual 
reassessment method and the posterior DLTs mean was calculated to confirm the MTD that 
was determined from the dose-escalation cohorts.
Following escalation to the next dose cohort, additional patients were enrolled to the dose-
expansion cohorts if the median decrease in FLT3 phosphorylation was ≥90% as determined 
by an ex vivo FLT3 plasma inhibitory activity (PIA) assay23 or if ≥1 subject achieved a 
complete remission (CR), CR with incomplete hematological recovery (CRi), or CR with 
incomplete platelet recovery (CRp; Table S1, Supplemental Appendix, page 3). If FLT3 
target inhibition was observed or CR/CRi/CRp occurred, and no DLTs were observed in the 
initial three patients, dose cohorts were expanded to include ≥14 additional patients. On the 
basis of emerging toxicity, pharmacokinetic/pharmacodynamic profile, and antileukemic 
response, the 120 and 200 mg dose cohorts were further expanded to include FLT3mut+ 
patients only.
Patients (≥18 years) with primary or secondary AML and Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤2 were eligible for enrollment if they were refractory 
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to ≥1 cycle of induction chemotherapy or had relapsed after achieving remission with a prior 
therapy. Although the presence of a FLT3 mutation was not an inclusion criterion, ≥10 
patients with locally confirmed FLT3 mutations (ITD or activating point mutation) were 
required to be enrolled in the expansion cohorts at each dose level. Other inclusion criteria 
were serum alanine or aspartate aminotransferase levels ≤2.5 × the institutional upper limit 
of normal (ULN), serum creatinine levels ≤1.5 × institutional ULN or an estimated 
glomerular filtration rate >50 ml/min. Patients who had congestive heart failure New York 
Heart Association (NYHA) class 3/4 were excluded; those who previously had NYHA class 
3/4 congestive heart failure were excluded, unless a screening echocardiogram performed 
within 3 months prior to study entry resulted in a left ventricular ejection fraction ≥45%. 
Patients with long QTc syndrome at screening and those with active uncontrolled infections, 
including hepatitis B or C infections and human immunodeficiency virus infection, were 
also excluded. Additional inclusion/exclusion criteria are detailed in the Supplemental 
Appendix (page 1).
Procedures
The first patient was treated at a starting dose of 20 mg/d; if no DLT occurred, the next 
patient was enrolled at the next dose level of 40 mg/d. Dose escalation ≤80 mg/d continued 
until the first instance of a DLT or second instance of a grade 2 AE judged by the 
investigator to be related to the study drug with the exception of hematologic toxicities. At 
doses >80 mg/d, three subjects were treated at each subsequent dose level (120 mg/d, 200 
mg/d, 300 mg/d, and 450 mg/d), such that if no DLTs were observed at a specific dose level, 
the subsequent three patients were treated at the next dose level. If a DLT was observed in 
one of three subjects at a particular dose level, three additional patients were enrolled at the 
same dose level; if two or more DLTs were observed at a specific dose level, DLT will be 
established and the next lower dose level will be established as the MTD. For the dose-
expansion cohorts, ≥10 patients with FLT3-ITD mutations were to be included at each dose 
level, and dose levels ≥120 mg/d were further expanded to include ≥42 FLT3mut+ patients on 
the basis of antileukemic response.
Patients received an initial oral gilteritinib dose (tablet) followed by a 48-hour observation 
and PK analysis period (Cycle 0). Starting on Day 1 Cycle 1, patients entered a repeated-
dose protocol and received once-daily oral gilteritinib in a 28-day cycle that continued 
uninterrupted in the absence of significant toxicity; all subsequent cycles followed this 
repeated-dose protocol, with patients continuing on protocol until a discontinuation criterion 
was met. In the original protocol, patients who achieved CR/CRp/CRi or partial remission 
(PR) were permitted to undergo hematopoietic stem cell transplantation (HSCT) after 
stopping gilteritinib treatment; however, a protocol amendment issued after enrollment had 
started allowed patients to re-enroll after HSCT and resume gilteritinib treatment 
(Supplemental Appendix, pages 1–2).
Dose interruptions were specified in cases of grade 2 retinopathy, and grade 3 non-
hematologic AEs that were at least possibly related to gilteritinib. After resolution of these 
toxicities, gilteritinib could be restarted at a lower dose. Dose reduction without interruption 
was also allowed for persistent myelosuppression after two cycles of therapy in patients who 
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had <5% bone marrow blasts and no extramedullary disease. Treatment discontinuations 
were specified for grade 3/4 retinopathy, any grade 4 non-hematologic toxicity that was at 
least possibly related to the study drug. For patients in the dose escalation cohort who 
received 20 to 40 mg/d gilteritinib, a single dose increase was permitted if CRc had not been 
attained after Cycle 1; dose increases were not permitted for other dose escalation cohorts. 
For patients in the dose expansion cohort, stepwise dose escalation was allowed if CRc had 
not been attained after Cycle 1.
Discontinuation criteria during the course of the study were withdrawal of consent, 
significant deviation from specified inclusion or exclusion criteria (subjects having a clinical 
benefit and no DLT could remain in the study after discussion with the medical monitor), no 
response (ie, no partial or composite remission) to treatment and according to the 
investigator’s opinion no longer deriving clinical benefit after 2 cycles of treatment; 
gilteritinib dose interruption for >15 days (subjects may resume treatment after discussion 
with the medical monitor if the dose interruption did not stem from a treatment-related 
adverse event [AE]); determination by the investigator that continuation of the study drug 
will be detrimental to the patient, loss to follow-up, and death. Posttreatment discontinuation 
criteria were withdrawal of consent, loss to follow-up, lapse of >3 years from the End of 
Treatment visit, or death.
Safety and tolerability were assessed by the study investigators. Both TEAEs and clinical 
laboratory evaluations were scheduled at screening, on Days −2 and −1 before Cycle 1; 
during Cycle 1 on Days 1, 4±1, 8±1, 15, and 22±1; during Cycle 2 on Days 1±3 and 15±1; 
during subsequent cycles on Day 1±3; and at the end-of-treatment visit (within 7 days of the 
last dose of the study drug). Assessment of TEAEs also occurred at the 30-day follow-up 
visit. Full details regarding clinical safety/tolerability as well as PK and PD assessments are 
presented in the Supplemental Appendix (page 2). The antileukemic response following 
treatment with gilteritinib was determined using modified International Working Group 
(IWG) criteria.24,12 Bone marrow aspirates and biopsies were obtained at the time of study 
entry and subsequently on the first day of Cycles 2 and 3. Bone marrow aspirate and 
biopsies were repeated at one month after achievement of first CRc to confirm response and 
every 3 cycles thereafter. All other patients underwent bone marrow assessments every 2 
cycles.
Outcomes
Primary endpoints were safety, tolerability, and PK profile of gilteritinib; secondary 
endpoints were the antileukemic effects of gilteritinib and evaluation of gilteritinib drug-
drug interactions (DDI). Exploratory endpoints were the antitumor activity of gilteritinib 
with respect to FLT3, C-CBL, and AXL mutations, effects of gilteritinib on biomarkers 
related to AML, relationship between the PK profile and the pharmacodynamic (PD) effects 
of gilteritinib, evaluation of AXL mutations and AXL expression, PIA, PD effects of 
gilteritinib with respect to FLT3, AXL, and S6 phosphorylation. Gilteritinib DDI and many 
of the exploratory endpoints findings are to be addressed in separate publications. 
Composite remission (CRc) rate was defined as the sum of patients achieving CR, CRi, and 
CRp. Overall response rate (ORR) was defined as the sum of patients achieving CRc and 
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PR. The duration of response (DOR) was defined as the time from the date of either first 
CRc or PR until the date of documented relapse of any time for subjects who achieve CRc or 
PR (relapse date – first CRc or PR disease assessment date + 1). Subjects who died without 
report of relapse were considered non-events and censored at their last relapse-free disease 
assessment date (last relapse-free assessment date – first CRc or PR disease assessment date 
+ 1). Subjects who discontinued the study for an allogeneic HSCT were considered non-
events and were censored at the time of HSCT. Other subjects who did not relapse during the 
study were considered non-events and were censored at the last relapse-free assessment date.
Tolerability and safety were based on local site-specific monitoring of DLTs and treatment-
emergent adverse events (TEAEs), as well as on physical examinations, clinical laboratory 
evaluations, and electrocardiogram (ECG) monitoring. A DLT was defined as an event that 
was considered possibly or probably related to treatment, which occurred within 30 days of 
the starting dose on Day −2 for the dose-escalation cohorts or during the 28-day cycle for 
the expansion cohorts. DLTs were any Grade ≥3 non-hematologic or extramedullary toxicity 
with the exception of anemia, anorexia, fatigue, Grade 3 infection, Grade 3 fever with 
neutropenia, Grade 3 diarrhea or nausea that did not require tube-feeding or total parenteral 
nutrition, or diarrhea that could be managed to Grade ≤2 with standard medications. Of note, 
hematological toxicities were not considered DLTs.
Statistical Analysis
Sample size was not based on a statistical power calculation but rather on study design. It 
was estimated that upwards of 270 patients would be enrolled and that this sample size 
would provide adequate information for the study objectives.
Safety endpoints were analyzed in the Safety Analysis Set (SAF), defined as all patients who 
took ≥1 dose of gilteritinib. A two-parameter Bayesian logistical regression model was used 
to determine the dose-toxicity relationship and to inform the determination of MTD.25 All 
AEs and clinical laboratory data were summarized using descriptive statistics. 
Pharmacokinetic effects were assessed in the Pharmacokinetic Analysis Set, which is a 
subset of the SAF for which sufficient plasma concentration data were available to enable 
derivation of ≥1 PK parameter. Blood samples were drawn from patients to assess PK and 
PD parameters. PK parameters were evaluated by cohort and reported using descriptive 
statistics; analysis of PD effects using PIA has been described previously.23 Antileukemic 
activity was assessed in the Full Analysis Set (FAS), defined as all enrolled patients who 
received ≥1 dose of drug and had ≥1 post-treatment data point. Remission rates, CRc rates, 
ORR, duration of confirmed response, and overall survival (OS) were summarized using 
descriptive statistics. The OS curves and median time-to-event variables were estimated 
using the Kaplan–Meier method. To explore the relationship between dose level and CR 
response, a dose-response model was fitted to the binary CR response with FLT3 mutation 
status and the first and second order of logarithm-transformed dose, as independent 
covariates for all patients from the dose-escalation and dose-expansion cohorts. The CR rate 
with two-sided 95% confidence interval (CI) for each dose level was estimated from this 
model. All statistical analyses were performed using SAS® (Version 9·3 or higher) software.
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STUDY OVERSIGHT
This study was designed by the study sponsor in collaboration with the investigators, and 
was conducted in accordance with Declaration of Helsinki ethical principles, Good Clinical 
Practices, principles of informed consent, and requirements of public registration of clinical 
trials (ClinicalTrials.gov Identifier, NCT02014558). Site-specific institutional review boards 
approved the protocol. Written informed consent was obtained from each subject at 
enrollment. Statistical analyses were performed by a statistician at Astellas Pharma, Inc. All 
authors were in agreement regarding submission of the manuscript and vouch for the 
completeness and accuracy of the data. Professional medical writers, paid for by the study 
sponsor, assisted with manuscript preparation and submission under the authors’ guidance.
ROLE OF THE FUNDING SOURCE
Astellas Pharma, Inc. provided funding for this trial and was involved in the development of 
the study protocol, and in data collection, analysis, and interpretation. Editorial and writing 
assistance during the development of the manuscript was supported by the funder. The 
corresponding author had full access to all of the data in the study and final responsibility for 
the decision to submit the paper for publication.
RESULTS
STUDY DISPOSITION
The first subject in this study was enrolled on October 15, 2013; the last patient was enrolled 
on August 27, 2015. In total, 265 patients were allocated to treatment at 28 sites across the 
United States and Europe (Table S2, Supplemental Appendix, page 4). As of November 
2015, 234 (88%) had discontinued treatment; 31 (12%) patients remained on treatment with 
a median treatment duration of 25·9 weeks (interquartile range [IQR]: 15–50). The SAF 
included 252 patients (n=23, dose escalation; n=229, dose expansion) enrolled across seven 
dose cohorts (20–450 mg); 13 of the 265 enrolled patients were excluded from the SAF 
because they did not receive treatment with the study drug. The FAS consisted of 249 
patients and the Pharmacokinetic Analysis Set comprised 19 patients. Demographics and 
baseline characteristics of patients in the SAF are presented in Table 1. FLT3-ITD mutation 
at screening was locally confirmed in 162 patients, FLT3-D835 in 13 patients, and dual 
FLT3-ITD-D835 in 16 patients; all 31 patients remaining on treatment at database lock 
carried a FLT3-ITD mutation. All patients in the SAF had received prior chemotherapy, 29% 
(n=73/252) had undergone prior HSCT, and 25% (n=63/252) had received a prior tyrosine 
kinase inhibitor (TKI), most commonly sorafenib (n=54; Table 1). Among patients who had 
received prior TKI therapy, 3 (1%) had received ≥2 TKIs; all three subjects received lower 
doses of gilteritinib (20 mg, n=1; 40 mg, n=2).
SAFETY AND TOLERABILITY PROFILE OF GILTERITINIB (20–450mg)
Treatment-emergent AEs occurring in ≥10% of the SAF by grade is provided in Table 2; a 
list of any TEAE of Grade ≥3 occurring in <10% of the SAF is provided in Table S3 
(Supplemental Appendix, pages 5–12). Commonly reported AEs considered related to 
gilteritinib were typical for AML therapies (diarrhea [16%; n=41/252], fatigue [15%; 
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n=37/252], elevated AST [13%; [n=33/252], elevated ALT [10%; n=24/252]). Dose 
reductions were required for 10% (n=25/252) of patients in the SAF. Additional data 
regarding on-study exposure to gilteritinib can be found in Table S4 (Supplemental 
Appendix, page 13). Adverse events commonly associated with dose reductions were 
diarrhea (1%; n=2/252) and fatigue (1%; n=3/252); serious AEs observed in ≥5% of SAF 
patients were febrile neutropenia (31%; n=78/252), progressive disease (17%; n=43/252), 
sepsis (14%; n=36/252), pneumonia (11%; n=27/252), acute renal failure (10%; n=25/252), 
pyrexia (8%; n=21/252), bacteremia (6%; n=14/252), and respiratory failure (6%; 
n=14/252). Of these serious AEs, febrile neutropenia (2%; n=5/252), acute renal failure (2%; 
n=5/252), pyrexia (1%; n=3/252), sepsis (1%; n=2/252), and bacteremia (0.4%; n=1/252) 
were considered related to treatment. Eleven of 252 patients (4%) had a maximum post-
baseline QTcF interval >500 ms, and 22 of 252 patients (9%) had a >60 ms change in their 
maximum post-baseline QTcF relative to baseline. One critically ill patient in the 120 mg 
dose cohort, with no cardiac comorbidities, experienced fatal ventricular fibrillation deemed 
possibly related to treatment. Of the 37 patients who underwent allogeneic transplantation, 
13 resumed gilteritinib treatment after HSCT; three of these patients died due to causes 
unrelated to gilteritinib.
Reasons for treatment discontinuation are presented in Table S5 (Supplemental Appendix, 
page 14); progressive disease (6%; n=15/252) and sepsis (3%; n=7/252) were the most 
common AEs that led to study discontinuation. Drug-related TEAEs leading to 
discontinuation occurred in 10% of patients (n=25/252). The most common drug-related AE 
that led to treatment discontinuation was elevated blood creatinine phosphokinase (1.2%; 
n=3/252 patients). For a complete list of drug-related AEs leading to treatment 
discontinuation, please refer to the Supplemental Appendix (Table S6, Supplemental 
Appendix page 15).
A total of 95 deaths occurred in the SAF; the causes of death are listed in Table 3. Seven 
deaths considered possibly/probably related to treatment were due to pulmonary embolism, 
respiratory failure, hemoptysis, intracranial hemorrhage, ventricular fibrillation, septic 
shock, and neutropenia (one each); four were considered DLTs (intracranial hemorrhage, 
pulmonary embolism, ventricular fibrillation, and septic shock). Gilteritinib MTD was 
established as 300 mg when two of the three patients enrolled in the 450 mg dose-escalation 
cohort experienced two DLTs (diarrhea and elevated aspartate aminotransferase [AST]). In 
patients who received 80–300 mg/d doses of gilteritinib in the dose escalation or expansion 
phases, treatment-related Grade ≥3 diarrhea occurred in the 120 mg/d (n=1) and 200 mg/d 
(n=2) dose groups; elevated AST occurred in the 80 mg/d (n=1), 200 mg/d (n=3), and 300 
mg/d (n=1) dose groups; and elevated alanine aminotransferase occurred in the 80 mg/d 
(n=1), 120 mg/d (n=1), and 200 mg/d (n=4) dose groups. The probability of experiencing a 
DLT was <20% for gilteritinib doses up to 200mg (Figure S1, Supplemental Appendix, page 
19).
PHARMACOKINETIC PROFILE AND PHARMACODYNAMIC EFFECTS OF GILTERITINIB
Gilteritinib plasma concentrations following oral daily dosing (20–450 mg) were generally 
dose proportional and showed substantial accumulation until steady state levels at treatment 
Perl et al. Page 9
Lancet Oncol. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Day 15 (Figure 2A and 2B; Table S7, Supplemental Appendix, page 16). Potent target 
inhibition was observed at all dose levels, which prompted expansion of all dose cohorts 
ranging from 20 to 300 mg/d. An exposure-related increase in inhibition of FLT3 
phosphorylation was observed with increasing gilteritinib plasma concentrations (Figure 
2C): ≥90% of FLT3 phosphorylation inhibition was observed by Day 8 in the majority of 
patients receiving ≥80 mg. In vivo inhibition of FLT3 occurred at all dose levels (Figure 2C).
ANTILEUKEMIC ACTIVITY OF GILTERITINIB
As noted with the inhibition of FLT3 phosphorylation, the antileukemic effects of gilteritinib 
were observed in all dose cohorts. Across the entire FAS (n=249), overall response rate 
(ORR) was 40% (CR=8%, CRp=4%, CRi=18%, PR=10%) with a median response duration 
of 17 weeks (95% CI: 14, 29); three patients had relapsed with a response duration that 
lasted less than 1 cycle and one patient had a response duration of 55 weeks prior to relapse) 
and median OS of 25 weeks (95%CI: 20, 30; Table 4). The ORR in FLT3mut+ patients (49%; 
CR=9%, CRp=5%, CRi=22%, PR=12%; n=191) was higher than in patients with FLT3WT 
(12%; CR=2%, CRp=0%, CRi=7%, PR=3%; n=58; Table 4 and Table S8, Supplemental 
Appendix, page 17). Similarly, FLT3mut+ patients had a greater reduction from baseline in 
bone marrow myeloblasts than patients with FLT3WT and greater percentage reductions in 
bone marrow myeloblasts were seen with gilteritinib doses ≥80 mg/day (Figure S2 A and B, 
Supplemental Appendix, pages 20–21). Among the FLT3mut+ patients who had received any 
prior TKI (n=57), ORR was 37% (CR=4%; n=2/57], CRp=4%; n=2/57, CRi=18%; 
n=10/57], PR=11%; n=6/57). The median OS and median DOR in patients who had received 
any prior TKI therapy was 20 weeks (95% CI: 11, 32) and 14 weeks (95% CI: 6, 55), 
respectively. None of the three subjects who had received ≥2 prior TKIs responded to 
treatment; however, all three these patients received low doses of gilteritinib (20 mg, n=1; 40 
mg, n=2). In FLT3mut+ patients who had received prior therapy with sorafenib (n=39), ORR 
was 49% (CR=5%; n=2/39], CRp=8%; n=3/39, CRi=26%; n=10/39, PR=10%; n= 4/39).
Of the 191 FLT3mut+ patients in the FAS, 70 (37%) achieved CR, CRi, or CRp; although 
CR, CRi, and CRp occurred at all doses (Figure 3A), responses occurred most frequently 
among FLT3mut+ patients receiving doses ≥80mg/d. The ORR in FLT3mut+patients receiving 
≥80 mg/d was 52% (CR=11%, CRp=6%, CRi=24%, PR=11%), versus 12% for FLT3WT, 
with a median OS of 31 weeks (95% CI: 24, 59; Table 3 and Figure 3B) and a median 
response duration of 20 weeks (95% CI: 14, 33).
The median time to best response for all FLT3mut+ patients at dosages ≥80 mg was 7·2 
weeks (95% CI: 4·3, 8·1); swimmer plots for all patients are shown in Figure S3 
(Supplemental Appendix, pages 22–27). The transplant rate for the entire FLT3mut+ patient 
population was 19% (n=36/191); the transplant rate for all FLT3mut+ patients who received 
gilteritinib doses ≥80 mg/d was 19% (n=32/169). A total of 35% (n=13/37) of transplanted 
patients resumed gilteritinib therapy after engraftment as maintenance therapy. Landmark 
analyses comparing OS rates in patients who underwent HSCT (n=37) with those who did 
not are presented in Figure S4 (Supplemental Appendix, page 28); 36 of the 37 patients 
(97%) who underwent HSCT harbored FLT3 mutations. The median OS in all FLT3mut+ 
responders who underwent HSCT (n=32), including patients who achieved PR, was 47 
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weeks (95% CI: 32, 61); in FLT3mut+ responders who did not undergo HSCT (n=61), 
median OS was 42 weeks (95% CI: 31, 48). The overall transplant rate for FLT3mut+ patients 
who achieved PR or better was 34% (n=32/93). Of all FLT3mut+ patients who achieved CRc 
(n=70), 47 (67%) had no prior transplant; 22 of these 47 patients (47%) underwent HSCT.
Among FLT3mut+ patients, ≥80 mg gilteritinib dosages were associated with antileukemic 
activity in both TKI-naive and prior TKI use subgroups with more frequent responses noted 
in TKI-naive patients (ORR=56% vs 42%, respectively; Supplemental Appendix Table S9, 
page 18). At these dosages, ORRs in patients with FLT3-ITD or both FLT3-ITD and -D835 
mutations were 55% and 62%, respectively; ORR in patients with FLT3-D835 mutations 
only was 17% (Supplemental Appendix Table S9, page 18). Of the 16 patients in the FAS 
who had only FLT3-D835 mutations, two responded to treatment with gilteritinib. One 
patient with only FLT3-D835 achieved CRi at Day 1 Cycle 2 but was not evaluable at Day 1 
of Cycle 3; response duration was one day because the patient was censored at the last 
relapse-free disease assessment date (ie, Cycle 2 Day 1). The other patient achieved PR at 
Day 1 Cycle 2 and relapsed at Day 1 of Cycle 3; the DOR was 5·9 weeks.
DISCUSSION
This first-in-human, biomarker-driven study confirms that gilteritinib is a highly specific, 
potent FLT3 inhibitor with antileukemic activity against FLT3-ITD mutations in the 
presence or absence of TKD mutations. Gilteritinib was well tolerated and displayed clinical 
activity across a wide therapeutic window in a heavily pretreated FLT3mut+ R/R AML 
population. Furthermore, gilteritinib demonstrated a long elimination half-life, supporting 
once-daily dosing. Correlative studies confirmed consistent, sustained, and potent FLT3 
kinase inhibition in patients receiving ≥80 mg/d. Responses in all FLT3mut+ patients 
receiving ≥80 mg/d occurred frequently and, regardless of whether patients underwent 
HSCT, were associated with prolonged survival (median OS, 31 weeks) compared with 
reported survival durations from studies of other cytotoxic salvage chemotherapy regimens 
(median OS, 15 to 20 weeks).26,27 The median duration of gilteritinib response in FLT3mut+ 
patients was 20 weeks. Because the protocol mandated early response confirmation followed 
by bone marrow evaluations every 8 to 12 weeks in responding patients as well as censoring 
of patients who died due to reasons unrelated to AML, an overestimation of response 
duration is unlikely.
Clinical response rates in FLT3mut+ were higher than in FLT3WT patients, which 
underscores the specificity of gilteritinib. Composite response rates in FLT3mut+ patients 
following treatment with gilteritinib were comparable with those reported for quizartinib.28 
However, unlike with quizartinib, high response rates were maintained when both FLT3-ITD 
and D835 mutations were present.15 Median OS with gilteritinib (25 weeks) was also longer 
than that reported in a phase 1 study of quizartinib (study population, 14 weeks; FLT3-ITD 
subgroup, 18 weeks).12 The ability of gilteritinib to generate sustained responses via FLT3 
inhibition, coupled with reasonable survival duration in all tested FLT3 mutation types, 
validates FLT3 as a therapeutic target in R/R AML. The 19% transplant rate for the 
FLT3mut+ population is not surprising given that several factors limit delivery of HSCT (eg, 
advanced age, donor availability, and prior HSCT). Almost one-third of patients in our study 
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had undergone prior HSCT and a substantial proportion were aged >70 years. The transplant 
rate reported herein is similar to that reported in a comparable R/R AML population in the 
Cephalon 204 study.26 Notably, the transplant rate among FLT3mut+ patients who had not 
received prior HSCT in our study was 47%; however, receipt of HSCT after gilteritinib 
therapy had little impact on OS, which in our landmark analysis was similar among 
transplanted and nontransplanted FLT3mut+ patients (47 vs 42 weeks, respectively). While a 
Mantel-Byar or a Cox-Time Dependent analysis would theoretically be of value to clarify 
this point, due to the small number of patients who underwent transplantation in this study 
(n=37), these analyses are not possible. Furthermore, the small number of patients who 
received gilteritinib maintenance after HSCT (n=13) limits any conclusions regarding the 
merits of this approach outside of confirming its feasibility.
Gilteritinib toxicity was modest and manageable in outpatient settings. As expected in R/R 
AML, neutropenic infections were common but treatment-related mortality from 
neutropenia was <1%. Prolongation of QTc interval occurred in only 4% of gilteritinib-
treated patients, which is lower than that reported for other FLT3 inhibitors such as 
quizartinib, although lower doses of quizartinib may minimize the incidence of QTc 
prolongation.12,28 Furthermore, the DLT rate curve and PD data support a large therapeutic 
window of active, tolerable gilteritinib doses ranging from 20–300 mg/d. The 120 mg/d dose 
was chosen as the starting dose for future studies as it can provide potent FLT3 inhibition 
and allow for dose modification without compromising tolerability or antileukemic effects; 
phase 3 testing of gilteritinib in FLT3mut+ R/R AML (NCT02421939) has been initiated.
Clinical responses were also observed in some FLT3WT patients. This may be related to 
AXL inhibition, other off-target TKI effects, and/or inhibition of cryptic FLT3 kinase 
activation (eg, from rare TKD mutations not detected by polymerase chain reaction or 
FLT3WT kinase activation through FLT3 ligand).29,30 Non-canonical activation of FLT3 
signaling may identify additional patient populations that could benefit from gilteritinib 
therapy.
The pharmacodynamics-driven design of the current study led to the conclusion that 
gilteritinib doses ≥80 mg/d were able to potently and consistently inhibit FLT3 in vivo. The 
large sample size derived from combining all dose groups ≥80 mg/d allowed us to gauge the 
impact of gilteritinib with greater precision in this R/R AML population and to place our 
results in the context of standard therapy. Relapsed/refractory FLT3mut+ AML patients have 
infrequent and often short-lived responses to standard salvage induction chemotherapy, 
resulting in few long-term survivors. Response rates and OS observed with gilteritinib in this 
study appear better than those reported in R/R AML patients receiving standard 
chemotherapy.26,27 This provides a rationale for Phase 3 development as a single agent in 
R/R FLT3mut+ AML; this trial is ongoing (NCT02421939).
Gilteritinib is one of several FLT3-targeted inhibitors that are currently in development. 
Midostaurin, as a single agent, was shown to frequently reduce peripheral blood blast counts 
in wild-type and FLT3mut+ AML but generated limited bone marrow blast reductions and 
clinical response was brief before disease progression.7 Midostaurin’s lack of mutation 
selectivity among responders, coupled with preclinical evidence of broad kinase inhibitory 
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activity, suggest that its efficacy may not be solely attributable to FLT3 inhibition. In a phase 
2b study of twice-daily midostaurin in R/R AML, 71% of patients with FLT3 mutations and 
42% of patients with FLT3WT had a reduction in blast counts; however, CR was not 
achieved.7 Thus, combining midostaurin with intensive cytotoxic chemotherapy or 
hypomethylating agents may be a better strategy than monotherapy. A survival benefit for 
the combination of midostaurin and intensive combination chemotherapy in newly 
diagnosed FLT3mut+ AML was recently reported.31,32
The benefit of combining chemotherapy with TKIs may not apply to all broad-spectrum 
FLT3 kinase inhibitors. Indeed, the addition of lestaurtinib to intensive chemotherapy in two 
British cooperative group studies of newly diagnosed FLT3mut+ AML patients under 60 
years of age failed to improve CR rate, relapse-free survival, or OS, and modestly increased 
gastrointestinal toxicity.33 Two German cooperative group randomized, phase 2, placebo-
controlled trials investigated sorafenib in combination with intensive chemotherapy for 
newly diagnosed AML (without selection for FLT3-ITD).34,35 The SORAML trial, 
conducted in patients aged <60 years, showed that the addition of sorafenib to intensive 
chemotherapy resulted in higher 3-year event-free survival (EFS) rates than placebo (40% 
and 22%, respectively; p=0.01). However, sorafenib yielded no improvement in OS and was 
associated with increased rates of grade ≥3 AEs.34 In the other study, sorafenib plus 
intensive chemotherapy in patients aged >60 years of age, failed to increase CR, EFS, or OS 
but was associated with treatment-related toxicity that led to therapy discontinuation.35 
Neither study demonstrated statistically significant improvement in CR, EFS, or OS in 
FLT3-ITD subgroups, although the number of patients with FLT3-ITD mutations in both 
trials was small.34,35 Evidence suggests that administration of sorafenib as a single agent 
after allogeneic HSCT may enhance treatment response in patients with FLT3-ITD 
mutations.36
While there is continued interest in combining FLT3 inhibitors with chemotherapy, there is 
also an interest in more potent FLT3 inhibitors with greater selectivity and reduced toxicity. 
Two such agents are quizartinib and crenolanib. Although quizartinib, a potent and selective 
once-daily FLT3 inhibitor, resulted in high CRc and ORR in R/R AML, durable survival 
generally necessitated HSCT37 and non-transplanted patients frequently developed 
resistance due to treatment-emergent FLT3-TKD mutations (eg, D835).38 In the phase 1 
study of quizartinib, median OS was 14 weeks for the entire study population and 18 weeks 
for patients with FLT3-ITD mutations.12 Two small, single-institution trials of crenolanib 
demonstrated significant antileukemic activity in R/R FLT3mut+ AML.39,40 However, due to 
crenolanib’s short half-life, thrice-daily dosing was required; CR or CRp rarely occurred, 
and nausea, vomiting, and hepatic toxicity were common.39,40
The main limitations of this study are that it was a non-randomized, single-arm, open-label 
study with a relatively small number of patients, which limits generalization of the findings 
to the AML population at large. Gilteritinib effectively inhibited FLT3 in most patients at all 
tested doses. As such, the small number of patients with submaximal target inhibition makes 
it challenging to prove that the potency of FLT3 inhibition predicts the depth of marrow 
response.
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More FLT3mut+ patients achieved CRi than CR or CRp, suggesting that minimal residual 
disease persisted following gilteritinib therapy. It should be noted that all potent FLT3 
inhibitors have a propensity toward generating CRis in FLT3mut+ R/R AML patients; the 
reasons for this outcome warrant further investigation. Some FLT3 inhibitors (eg, 
quizartinib) are also potent c-Kit inhibitors with substantial myelosuppression effects.12,28 In 
contrast, FLT3 inhibition induces terminal granulocytic differentiation of leukemic blasts in 
most responders, which may explain robust neutrophil recovery.41 Generation of 
erythrocytes and platelets in responders to FLT3 inhibitors presumably occurs from 
background hematopoiesis rather than differentiation. Erythropoiesis and megakaryopoiesis 
are frequently and persistently suppressed in the context of massive clonal expansion of 
FLT3mut+ cells undergoing differentiation during FLT3 inhibitor response. Finally, it is likely 
that differentiation abnormalities in pre-leukemic clones limit production of all 
hematopoietic lineages, especially among patients who were previously diagnosed with 
myelodysplastic syndrome. Therefore, administration of a drug that selectively targets a 
single mutation arising from a genetically complex and clonally diverse bone marrow 
environment, will likely unmask the underlying disordered hematopoietic capacity of the 
remaining bone marrow cells.
Changes in allelic burden during therapy were not formally investigated here, although 
evidence suggests that many patients respond to FLT3 inhibitors via clonal differentiation 
rather than a direct cytotoxic response that clears the FLT3-mutated cells from the marrow.41 
Although FLT3-ITD and D835 are both activating and transforming oncogenes, in vitro data 
suggest that they activate different downstream signaling networks.42 These signaling 
differences could contribute to varying level of oncogene addiction in the R/R setting and 
thus different clinical effects in the setting of kinase inhibition, specifically lower response 
rates among patients with FLT3-D835 only. However, while it is possible that FLT3-D835 in 
the absence of FLT3-ITD is a weaker driver and generates a lesser degree of oncogene 
addiction, the small number of patients with D835 mutations in this study limits the strength 
of any conclusions regarding the antileukemic activity of gilteritinib in this population due to 
the large CI. Finally, the potential impact of additional mutations on the depth of response or 
development of primary acquired resistance to gilteritinib requires further elucidation.
In conclusion, gilteritinib monotherapy was well tolerated, generated high response rates and 
durable survival in FLT3mut+ R/R AML patients, including those with both FLT3-ITD and 
D835 mutations. Because gilteritinib as a single agent is likely to have limited curative 
capacity even when used early in the disease course, studies that integrate gilteritinib into 
front-line chemotherapy regimens are underway. These include trials of gilteritinib in 
combination with standard induction chemotherapy and high-dose cytarabine consolidation 
therapy (NCT02236013) or with azacitidine (NCT02752035). A placebo-controlled trial of 
gilteritinib as maintenance therapy for patients in first remission receiving allogeneic HSCT 
(NCT02997202) will be initiated. Overall, our study both confirms that FLT3 is a high-value 
target in R/R AML and demonstrates that long-term success of therapeutic FLT3 inhibition 
is optimized by agents with potent, selective, and sustained activity against FLT3-ITD 
mutations as well as TKD mutations.
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RESEARCH IN CONTEXT
Evidence before this study
Despite the major advances in our understanding of leukemogenesis, effective treatment 
of acute myeloid leukemia (AML) remains a challenge due to disease heterogeneity, drug 
toxicity, and treatment resistance. For patients with an adverse genetic risk profile, 
relapse occurs frequently and prognosis thereafter remains bleak. Activating mutations in 
fms-like tyrosine kinase 3 (FLT3) have been correlated with an increased risk of relapse 
and subsequent poor survival due to chemotherapy resistance. Therefore, inhibition of 
FLT3 activity is a key therapeutic strategy in AML. A search of Medline and PubMed 
databases with no established date limit was conducted using the search terms ‘FLT3 
inhibitors’, ‘sorafenib’, and ‘midostaurin’ in the context of clinical studies in AML, 
yielded 40 publications; meeting abstracts, review articles, meta-analyses, and case 
studies were excluded. The majority of clinical studies of FLT3 tyrosine kinase inhibitors 
were small-scale, single-arm, nonrandomized Phase 1 or Phase 2 studies. Of the limited 
number of published placebo-controlled Phase 3 studies, none had examined the effects 
of single-agent FLT3 tyrosine kinase inhibitors. Phase 3 studies of lestaurtinib examined 
the agent in combination frontline or salvage therapy regimens, and showed no 
statistically significant clinical response or survival benefit. It is also important to note 
that enrichment for FLT3 mutations is lacking in many clinical studies of FLT3 
inhibitors. Furthermore, the current clinical literature is limited to first-generation FLT3 
inhibitors that have limited specificity, short-lived antileukemic activity, and the potential 
for toxicity stemming from off-target effects. Several second-generation FLT3 inhibitors 
have been developed, which partially addresses these limitations. However, published 
data show persistent toxicity concerns as well as frequent generation of treatment 
emergent FLT3 tyrosine kinase domain mutations that confer resistance and limit the 
durability of observed clinical benefits. Particularly, FLT3-D835 mutations stand out as a 
frequent and vexing mechanism of resistance to FLT3 inhibitors.
Added value of this study
Gilteritinib is a highly potent and selective tyrosine kinase inhibitor with in vitro activity 
against FLT3 internal tandem duplication mutations and tyrosine kinase domain 
mutations. The current phase 1/2 study of once-daily oral gilteritinib had an innovative 
pharmacodynamic-driven trial design that enabled rapid identification of optimal dosing 
in a FLT3 mutation-enriched R/R AML population. Our results demonstrated that 
gilteritinib was generally well tolerated and produced sustained potent FLT3 inhibition, 
which correlated with frequent clinical responses and promising survival data. Response 
extended to patients predicted to be resistant to this class of agents, such as those with 
both FLT3-ITD and D835 mutations, as well as those with prior FLT3 inhibitor exposure. 
Findings from this study lay the foundation for phase 3 studies comparing gilteritinib 
against standard chemotherapy or other targeted agents.
Implications of all the available evidence
Emerging targeted therapies offer promise in patients with R/R AML. Disease in these 
patients is unlikely to durably respond to conventional chemotherapy regimens. As 
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demonstrated in the current study, a potent, highly selective FLT3 inhibitor with activity 
against common resistance mechanisms allows for better tolerability and a sustained 
treatment response. These data convincingly validate FLT3 as a high-value therapeutic 
target in AML.
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Figure 1. Study Design and Accrual
* Three evaluable subjects
** Enrollment stopped early for low response rate
CR, complete remission; CRi, complete remission with incomplete hematologic recovery; 
CRp, complete remission with incomplete platelet recovery; DLT, dose-limiting toxicity; 
FLT3, Fms-like tyrosine kinase 3
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Figure 2. Gilteritinib Pharmacokinetic Profile and Pharmacodynamic Effects
A) Gilteritinib plasma concentrations over the 24-hour dosing period following a single dose 
(Cycle 0 Day −2).
B) Gilteritinib plasma concentrations over the 24-hour dosing period following multiple 
doses (Cycle 1 Day 15).
C) Plasma inhibitory activity assay results.
Graphs depicting gilteritinib plasma concentrations over the 24-hour dosing period are 
representative of the following numbers of patients in each dose cohort: 20mg/d, n=4; 
40mg/d, n=3; 80mg/d, n=3; 120mg/d, n=3; 200mg/d, n=2; 300mg/d, n=3; 400mg/d, n=1. 
Plasma samples from patients treated at different dose levels were assayed for inhibitory 
activity against FLT3-ITD receptors in Molm14 cells using immunoblotting as described in 
the Methods section. (Left) Each filled circle represents a sample from a single patient at the 
indicated dose level, collected immediately prior to dosing on Day 15 Cycle 1. For each dose 
level, the mean plasma inhibitory activity result is indicated by a red line. For each point, the 
reference sample was collected immediately prior to the first dose on Day 1 Cycle 1. (Right) 
Representative immunoblots of PIA assays from pre- and post-dose on Days 1, 8, and 15 of 
Cycle 1 are shown.
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Figure 3. Clinical Response to Gilteritinib (≥80mg) in FLT3-Mutation-Positive Relapsed/
Refractory AML Patients
A) Overall clinical response, by dose, in patients with FLT3-mutation-positive R/R AML.
CR, complete remission; CRi, complete remission with incomplete hematologic recovery; 
CRp, complete remission with incomplete platelet recovery; PR, partial remission. 
Composite response (CRc=CR+CRi+CRp) and overall response (ORR=CRc+PR) are noted 
in bold type.
B) Kaplan–Meier curve showing the overall survival of patients receiving ≤40mg gilteritinib 
versus ≥80mg gilteritinib.
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Table 4
Antileukemic Response to Gilteritinib in Patients With R/R AML
Antileukemic Response
FAS Patient Population 
(n=249) FLT3WT (n=58)
FLT3mut+
All Patients (n=191)
Patients Receiving ≥80mg/d 
(n=169)
CR 19 (8% [5, 12]) 1 (2% [0, 9]) 18 (9% [6, 15]) 18 (11% [6, 16])
CRp 10 (4% [2, 7]) 0 10 (5% [3, 9]) 10 (6% [3, 11])
CRi 46 (19% [14, 24]) 4 (7% [2, 17] 42 (22% [16, 29]) 41 (24% [18, 31])
PR 25 (10% [7, 15]) 2 (3% [0, 12]) 23 (12% [8, 18]) 19 (11% [7, 17])
CRca 75 (30% [25, 36]) 5 (9% [3, 19]) 70 (37% [30, 44]) 69 41% (33, 49)
ORRb 100 (40% [34, 47]) 7 (12% [5, 23]) 93 (49% [41, 56]) 88 (52% [44, 60])
Median response durationa 17 (14, 29) 12 (3, 17) 20 (14, 33) 20 (14, 33)
Median overall survivalb 25 (20, 30) 17 (11, 21) 30 (23, 33) 31 (24, 59)
CI, confidence interval; CR, complete remission; CRc, composite remission (CR+CRp+CRi); CRp, complete remission with incomplete platelet 
recovery; CRi, complete remission with incomplete hematologic recovery; FAS, full analysis set; PR, partial response; ORR, overall response rate 
(CRc+PR)
Data presented as n (% [95% CI]) unless otherwise noted.
a
Data presented as % (95% CI).
b
Data presented as weeks (95% CI).
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